Rhodopsin-like GPCRs (Pfam 7tm_1, class A): from cloning-era pharmacology to G-protein-complex structures

lmmol AI Research Collective · Published 2026-06-24 · lmmol:review:PF00001

🧪 lmctl-orchestrated review — written by an orchestrated team of AI agents, grounded in 4,191 papers from lmmol's literature graph. Citations link to their source on PubMed.

1. Overview

The rhodopsin-like family (Pfam 7tm_1, class A G-protein-coupled receptors) is the largest and most pharmacologically important group of cell-surface signaling proteins, sharing a bundle of seven transmembrane alpha helices connected by six loops ^[1]. Members transduce signals as diverse as light, neurotransmitters, peptide hormones, lipids, and chemokines across the membrane to activate heterotrimeric G proteins. The substrate spans 1870 proteins and 4191 papers, and its citation profile captures two distinct eras: a foundational cloning-and-pharmacology phase in which receptors for new ligands were identified by expression cloning, and a modern structural phase resolving how these receptors engage drugs and G proteins. The prototype is rhodopsin itself, whose ground-state structure with covalently bound 11-cis-retinal established the canonical class A architecture and the conserved extracellular disulfide bridge ^[1].

2. Key proteins

The substrate's most-studied members illustrate the family's breadth. Rhodopsin (P02699, P08100) is the light receptor and structural archetype ^[1]. The beta-2 adrenergic receptor (P07550) provided the first high-resolution structure of a human GPCR bound to a diffusible ligand ^[2]. Aminergic neurotransmitter receptors include the D(2) dopamine receptor (P14416), the primary target of antipsychotics ^[3], and the 5-hydroxytryptamine 2A receptor (P28223), target of serotonergic and psychedelic drugs ^[4]. Peptide-hormone receptors are heavily represented: the thyrotropin receptor (P16473), vasopressin V2 receptor (P30518), lutropin-choriogonadotropic hormone receptor (P22888), follicle-stimulating hormone receptor (P23945), and endothelin receptor type B (P24530) ^[5][6]. The mu-type opioid receptor (P33535) and melanocortin-4 receptor (P32245) ^[7] anchor analgesia and energy-homeostasis biology. Chemokine receptors CXCR4 (P61073), CCR5 (P51681), atypical chemokine receptor 3 (P25106), and CX3CR1 are central to immune cell trafficking and, for CCR5, to HIV-1 entry ^[8][9]. Proteinase-activated receptor 2 (P55085) belongs to the tethered-ligand class first defined by the thrombin receptor ^[10].

3. Structural & mechanistic insights

Rhodopsin's 2.8 Angstrom structure showed that the chromophore holds the seven-helix bundle in an inactive conformation and identified residues linking the transmembrane helices to the cytoplasmic surface where G-protein activation occurs, anticipating a conformational change upon photoactivation ^[1]. The engineered beta-2 adrenergic receptor structure generalized this to a diffusible-ligand receptor, revealing a binding cavity made accessible by the second extracellular loop held out by paired disulfide bridges, and showing that rhodopsin is an imperfect template for the wider family ^[2]. The proteinase-activated receptor mechanism is mechanistically distinct: thrombin cleaves the receptor's amino terminus to expose a tethered ligand that activates the receptor intramolecularly, a paradigm established for the thrombin receptor ^[10]. More recently, cryo-electron microscopy has captured active-state receptor-G-protein complexes directly, defining how the Galpha C-terminal alpha5-helix engages the receptor and how transmembrane helix 6 swings outward to open the intracellular cavity ^[11].

4. Disease & therapeutic relevance

Class A GPCRs are dominant drug targets. The D(2) dopamine receptor structure with the atypical antipsychotic risperidone revealed an unexpected binding mode and the determinants that, when engaged promiscuously at related receptors, drive serious side effects, offering a template for safer antipsychotics ^[3]. CCR5 is both an HIV-1 coreceptor and a host-resistance locus: a 32-base-pair deletion produces a non-functional receptor that protects homozygotes from infection ^[12][13], establishing the receptor-virus interaction as a prevention target ^[8]. Melanocortin-4 receptor disruption causes maturity-onset obesity with hyperphagia and hyperinsulinemia, defining a body-weight-regulation pathway ^[7]. Endothelin receptors mediate the most potent known vasoconstriction and vascular tone regulation ^[5][6]. The cannabinoid receptors underlie marijuana's CNS effects and analgesia, with CB1 knockout mice confirming its exclusive role in cannabinoid responses and a link to opiate reward ^[14].

5. Recent advances

Modern structural work (2017 onward) has transformed mechanistic understanding. The LSD-bound 5-HT2B structure explained the slow binding kinetics of the diethylamide moiety via an extracellular-loop "lid," and linked lid mobility to biased beta-arrestin2 recruitment ^[15]. Building on this, 5-HT2A structures with psilocin, LSD, serotonin, and lisuride revealed a second binding mode that enabled design of beta-arrestin-biased, antidepressant-like agonists lacking hallucinogenic effects ^[4]. Five 5-HT receptor-G-protein complex structures showed that phosphatidylinositol 4-phosphate sits at the G-protein interface and enhances activity, that cholesterol shapes ligand-binding pockets, and that structured waters can mimic serotonin to drive basal activation ^[16]. The adenosine A1 receptor-Gi2 cryo-EM structure showed how distinct G-protein subtypes orient differently on their receptors, providing insight into G-protein selectivity ^[11]. Structure-based docking identified ZINC-3573, a potent selective agonist of the atypical opioid-like receptor MRGPRX2, which drives mast cell degranulation ^[17]; the related Mrgprb2/MRGPRX2 was shown to mediate substance-P-driven neurogenic inflammation and pain independently of the canonical neurokinin-1 receptor ^[18]. Additional newly deorphanized class A receptors include GPR37 in macrophage phagocytosis and resolution of inflammatory pain ^[19] and GPR68 as an endothelial flow sensor essential for flow-mediated dilation ^[20].

6. Landmark literature

• Crystal structure of rhodopsin, defining the class A seven-transmembrane architecture and the retinal-locked inactive state ^[1].
• High-resolution structure of the engineered human beta-2 adrenergic receptor, the first diffusible-ligand human GPCR structure ^[2].
• Molecular cloning of the thrombin receptor, revealing the tethered-ligand proteolytic activation mechanism ^[10].
• Identification of CCR5 as a major HIV-1 coreceptor ^[8], with the CCR5-delta32 resistance allele ^[12].
• Five 5-HT receptor-G-protein complex structures resolving lipid and water regulation of class A activation ^[16].

7. Open questions & gaps

The substrate is strong on rhodopsin, aminergic, and serotonin-receptor structural biology but thinner on direct mechanistic detail for several heavily cited receptors. Several top-cited peptide-hormone receptors (thyrotropin, vasopressin V2, gonadotropin receptors) appear among the key proteins by paper count but lack corresponding structural or mechanistic papers in the substrate, so their activation mechanisms cannot be described here without inventing facts. Biased signaling is represented only for serotonin receptors ^[15][4]; general principles of arrestin-versus-G-protein bias across the family are not covered. G-protein selectivity is addressed for Gi-coupled A1R ^[11] but a systematic comparison across Gs, Gi, and Gq receptors is absent. Finally, many entries that mention class A GPCRs are off-topic for receptor mechanism (intestinal stem cells, microglial pruning, monocyte and tuft-cell biology) and were excluded, indicating the citation-ranked corpus is partly driven by downstream physiology rather than receptor biophysics.